Can I increase lisdexamfetamine to the maximum approved dose of 70 mg and add another long‑acting stimulant for off‑label optimization?

Lisdexamfetamine Dose Optimization: Maximum Dose Plus Adjunctive Long-Acting Stimulant

Do not combine lisdexamfetamine 70 mg with another long-acting stimulant for off-label optimization. The maximum FDA-approved dose of lisdexamfetamine is 70 mg daily, and exceeding this through combination therapy lacks evidence for improved efficacy while increasing cardiovascular and psychiatric risks 1.

Rationale Against Combination Therapy

FDA-Approved Maximum Dosing

The FDA label explicitly states that lisdexamfetamine should be titrated to a maximum of 70 mg daily 1. This ceiling was established through dose-ranging studies showing that:

• 30 mg, 50 mg, and 70 mg doses all demonstrated superiority over placebo in both pediatric and adult populations 1
• The 70 mg dose represents the highest dose studied in clinical trials 2
• No data exists on doses above 70 mg/day to inform safety or efficacy 2

Evidence on Dose-Response Relationship

Research indicates a dose-dependent response up to 70 mg, but with important caveats 2:

• Higher doses (50-70 mg) produced greater ADHD-RS-IV score improvements compared to 30 mg
• Patients with greater baseline severity benefited more from higher doses, particularly for hyperactive-impulsive symptoms 3
• However, approximately 14% of patients assigned to 70 mg could not tolerate this dose during forced titration 2

Safety Concerns with High-Dose Stimulants

A retrospective study examining doses exceeding manufacturer recommendations found 4:

• Children on high-dose stimulants experienced significantly more growth attenuation (Δ height z-score -0.41 vs -0.09, p=0.001; Δ weight z-score -0.56 vs -0.18, p=0.002)
• Growth suppression occurred primarily before reaching the high-dose range, suggesting cumulative effects
• While no serious complications were reported, the study was limited by retrospective design and small sample size

Cardiovascular Risks

Long-term lisdexamfetamine treatment (up to 2 years) demonstrated 5:

• Mean increases in pulse rate (+7.0 bpm), systolic BP (+3.4 mmHg), and diastolic BP (+3.2 mmHg)
• 22.4% of children and 15.2% of adolescents met thresholds for potentially clinically important high systolic BP
• 38.8% of children and 21.4% of adolescents met thresholds for potentially clinically important high diastolic BP

Adding another long-acting stimulant would compound these cardiovascular effects without established safety data.

Alternative Strategies When 70 mg Is Insufficient

First-Line Adjunctive Options

If lisdexamfetamine 70 mg provides inadequate symptom control, add a non-stimulant medication rather than another stimulant 6:

Extended-release guanfacine or extended-release clonidine are the only FDA-approved adjunctive therapies with stimulants 6:

• Both have evidence supporting combination use with stimulants
• Provide "around-the-clock" symptom coverage 7
• Different mechanism of action (alpha-2 adrenergic agonism) complements stimulant effects

Atomoxetine can be used off-label as adjunctive therapy 6:

• Limited evidence supports combining with stimulants
• Provides continuous 24-hour coverage
• May be particularly useful for comorbid anxiety or tics

Dosing Considerations for Adjunctive Therapy

When adding guanfacine or clonidine 7:

• Start low and titrate slowly (2-4 weeks to full effect)
• Monitor for somnolence/sedation (administer in evening if problematic)
• Check pulse and blood pressure regularly
• Taper gradually when discontinuing to avoid rebound hypertension

Reassess the Clinical Picture

Before escalating therapy, evaluate 6:

1. Medication timing: Does coverage extend through the entire day when needed?
2. Comorbidities: Are untreated anxiety, depression, sleep disorders, or oppositional defiant disorder contributing to apparent treatment resistance?
3. Adherence: Is the patient taking medication consistently as prescribed?
4. Environmental factors: Are behavioral interventions and accommodations optimized?
5. Substance use: In adolescents/adults, screen for diversion or substance abuse 8

Consider Switching Stimulant Class

If lisdexamfetamine 70 mg is ineffective, switch to methylphenidate-based long-acting formulations rather than adding another amphetamine 9, 7:

• Different pharmacokinetic profiles may provide better individual response
• Approximately 70-80% of patients respond to stimulants, but individual response varies by medication class
• This avoids supra-therapeutic amphetamine exposure

Common Pitfalls to Avoid

Do not assume "more is better" beyond FDA-approved dosing 9:

• The 2002 AACAP guidelines note: "If the top recommended dose does not help, more is not necessarily better. A change in drug or environmental or psychosocial intervention may be required" 9

Do not combine two long-acting amphetamine formulations:

• This creates unpredictable pharmacokinetics
• Substantially increases cardiovascular and psychiatric adverse event risk
• Lacks any evidence base for efficacy or safety

Do not neglect behavioral interventions 8, 6:

• Medication should be provided in parallel with psychosocial treatments
• Parent training, behavioral modification, and school accommodations remain essential

Monitor growth parameters closely in children 5:

• Weight and height at each visit
• Calculate BMI and plot growth curves
• Consider "drug holidays" if growth suppression is significant, though this must be balanced against symptom control needs